Tipranavir (Aptivus): Uses, Risks, And Dosing Guide
Comprehensive guide to Tipranavir (Aptivus), a key protease inhibitor for treatment-experienced HIV patients resistant to multiple therapies.
Tipranavir (brand name Aptivus) is a non-peptidic protease inhibitor specifically indicated for combination antiretroviral treatment of HIV-1 infection in highly treatment-experienced adults and adolescents aged 12 years and older with viral strains resistant to multiple protease inhibitors.
About tipranavir
Tipranavir, marketed as Aptivus, belongs to the class of non-peptidic HIV-1 protease inhibitors. Unlike traditional peptidomimetic PIs, tipranavir’s unique chemical structure provides activity against multidrug-resistant HIV-1 strains, making it valuable for salvage therapy in patients who have failed prior regimens. It works by selectively inhibiting the HIV-1 protease enzyme, which is essential for cleaving viral polyproteins (Gag and Gag-Pol) into functional components needed for mature, infectious virions. This disruption prevents the formation of new virus particles.
Tipranavir must always be co-administered with low-dose ritonavir, a pharmacokinetic booster that inhibits the CYP3A4 enzyme, substantially increasing tipranavir’s plasma concentrations and half-life. Without ritonavir boosting, tipranavir levels would be subtherapeutic. Clinical approval occurred in 2005 in the US and Europe for treatment-experienced patients, with indications extending to those aged two years and above in some regions when combined with other antiretrovirals.
In highly pretreated individuals, tipranavir/ritonavir (500/200 mg twice daily) has demonstrated superior viral suppression compared to other boosted PIs like lopinavir, indinavir, saquinavir, or amprenavir. Pivotal RESIST-1 and RESIST-2 trials showed treatment response rates of 33.6% versus 15.3% for comparators at 48 weeks, with even greater benefits (up to 48.5%) when combined with enfuvirtide or other active agents.
Before taking tipranavir
Allergy
Do not take tipranavir if you are allergic (hypersensitive) to tipranavir, ritonavir, or any ingredients in Aptivus formulations (capsules or oral solution). Allergic reactions may include rash, itching, swelling, or anaphylaxis. Inform your doctor immediately if such symptoms occur.
Pregnancy and breastfeeding
Tipranavir’s safety in pregnancy is not fully established, classified as FDA Pregnancy Category C. Animal studies show no direct teratogenicity, but it is recommended only if benefits outweigh risks. Effective contraception is advised during treatment. HIV-positive women should not breastfeed to avoid postnatal transmission, regardless of maternal viral suppression.
Babies and children
Aptivus is approved for children aged 2 years and older in combination with ritonavir and other antiretrovirals. Dosing is weight-based: for ages 2-12 years, 14 mg/kg (capsules/oral solution) or 12 mg/kg (if >15 kg) of tipranavir plus age-appropriate ritonavir, twice daily. Use requires careful monitoring for adherence and side effects in pediatric populations.
Other medicines – interactions
Tipranavir/ritonavir has a complex interaction profile due to strong CYP3A4 inhibition and induction effects. Key interactions include:
- Contraindicated: Drugs reliant on CYP3A for metabolism (e.g., alfuzosin, sildenafil for PAH, pimozide, quinidine, rifampin, St. John’s wort, ergot derivatives).
- Requires dose adjustment: Anticoagulants (e.g., warfarin), antifungals (e.g., fluconazole), statins (atorvastatin max 20 mg/day; avoid simvastatin, lovastatin), methadone (may need increase).
- HIV drugs: Compatible with most NRTIs, NNRTIs (efavirenz requires caution), enfuvirtide; avoid unboosted PIs.
Always provide your doctor a full medication list, including herbal supplements.
Medicines that do not mix well with tipranavir
| Drug Class | Examples | Reason |
|---|---|---|
| Antiarrhythmics | Amiodarone, bepridil | Potential cardiac toxicity |
| Antimycobacterials | Rifampin | Decreases tipranavir levels |
| Herbals | St. John’s wort | Induces metabolism, reduces efficacy |
| HMG-CoA reductase inhibitors | Simvastatin, lovastatin | Myopathy risk |
| Sedatives | Midazolam, triazolam | Increased sedation |
Consult product labeling or a specialist for comprehensive lists.
How and when to take tipranavir
Dosage
Adults and adolescents ≥12 years: 500 mg tipranavir capsules/oral solution + 200 mg ritonavir, twice daily with food. Capsules must be swallowed whole; oral solution for those unable to swallow capsules (contains vitamin E; monitor intake).
Pediatrics (2-12 years): Weight-based dosing as noted, max 500/200 mg BID.
Take it with or without food?
Always take with a meal (high-fat food enhances absorption by ~30%). Shake oral solution well before use.
If you forget a dose
Take as soon as remembered unless near next dose; do not double. If regimen disrupted >7 days, consult physician for viral load check.
How long to take it for
Lifelong as part of ART unless resistance develops or intolerance occurs. Regular monitoring of viral load/CD4 ensures efficacy.
If you take too much tipranavir
Overdose symptoms: nausea, diarrhea, elevated liver enzymes. Seek immediate medical attention; no specific antidote. Supportive care and monitoring advised.
Stopping tipranavir
Do not stop without medical advice; abrupt discontinuation risks resistance and viral rebound. Transition to alternative ART guided by resistance testing.
Side-effects
Tipranavir is generally well-tolerated but associated with hepatotoxicity (clinical hepatitis in 7-15%, higher in HBV/HCV coinfection), rash (14%, including Stevens-Johnson/ toxic epidermal necrolysis rarely), gastrointestinal effects (diarrhea 20-25%), and intracranial hemorrhage (rare, 0.5%). Lipid elevations common; monitor LFTs, lipids, triglycerides frequently.
- Common (>1/10): Diarrhea, nausea, vomiting, abdominal pain.
- Serious (seek help): Jaundice, dark urine, severe rash, bleeding/bruising, fat redistribution.
Common questions about tipranavir
How does tipranavir work?
It inhibits HIV protease, preventing viral maturation.
Who is tipranavir for?
Treatment-experienced patients with PI-resistant HIV-1.
Does tipranavir cure HIV?
No, it suppresses replication; not curative.
Can tipranavir be used in children?
Yes, from age 2 with weight-based dosing.
What if I miss a dose?
Take promptly; resume schedule.
Analyses from X users
(Note: As this is a medical article, real-time X analyses are omitted for factual accuracy; consult healthcare provider.)
References
- Tipranavir: a review of its use in the management of HIV infection — Drugs. 2008-06-23. https://pubmed.ncbi.nlm.nih.gov/18578560/
- Tipranavir: Uses, Interactions, Mechanism of Action — DrugBank. 2026 (updated). https://go.drugbank.com/drugs/DB00932
- Review of tipranavir in the treatment of drug-resistant HIV — PMC – NIH. 2008-04-30. https://pmc.ncbi.nlm.nih.gov/articles/PMC2374948/
- Aptivus | European Medicines Agency (EMA) — EMA. 2026 (updated). https://www.ema.europa.eu/en/medicines/human/EPAR/aptivus
- Tipranavir (Aptivus) — CATIE. 2026 (updated). https://www.catie.ca/tipranavir-aptivus
Similar Articles
Read full bio of Sneha Tete
